Inhalable Artificial Polymeric Nucleases Degrading Neutrophil Extracellular Trap-DNAs and Alleviating Pulmonary Fibrosis.

Adv Sci (Weinh)

School of Materials Science and Engineering, Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education, Sun Yat-sen University, Guangzhou, 510275, China.

Published: June 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Pulmonary fibrosis resulting from recurrent lung inflammation due to pathogen infection may lead to serious problems and death. Neutrophil extracellular traps (NETs), consisting of DNAs and proteins released by neutrophils in response to infection, are major pathogenesis factors for pathogen-associated pulmonary fibrosis. By mimicking nucleic acid hydrolase, polymeric artificial DNases bearing imidazole units (PEG-PIm) are developed to degrade the DNAs and thus deconstruct NETs, inhibiting pulmonary fibrosis. By tailoring the PIm segments with varied imidazole units, the polymer hydrolase with a defined number of imidazole units outperforms other samples in the cleavage of DNAs and inhibits the transition of pulmonary fibroblasts to myofibroblasts. This polymer digests the DNAs complexed with cationic peptides, unlike natural DNase I. By aerosol inhalation, it reduces NET infiltration in lungs and significantly alleviates inflammatory cytokines and fibrosis. Molecular dynamics simulations indicate that the optimized polymer may expose more effective imidazole units to the DNA backbones and thus enhance the affinity and hydrolysis of phosphodiester linkages. The function is also confirmed by systematic administration of PEG-PIm to rheumatoid arthritis. Thus, a strategy is provided for treating pulmonary fibrosis that can be applied in a pandemic to reduce high mortality because of pathogen infection.

Download full-text PDF

Source
http://dx.doi.org/10.1002/advs.202505357DOI Listing

Publication Analysis

Top Keywords

pulmonary fibrosis
20
imidazole units
16
neutrophil extracellular
8
pathogen infection
8
pulmonary
6
fibrosis
6
inhalable artificial
4
artificial polymeric
4
polymeric nucleases
4
nucleases degrading
4

Similar Publications

Baricitinib Combination Therapy Demonstrates Significant Improvement in Cardiac Conduction Defects in Rapidly Progressive Systemic Sclerosis: A Case Report.

Open Access Rheumatol

August 2025

Department of Rheumatology and Immunology, the First Affiliated Hospital, Jinan University, Guangzhou, 510632, People's Republic of China.

Objective: To evaluate the efficacy of baricitinib in combination therapy for managing refractory, rapidly progressive systemic sclerosis (SSc) with severe cardiac conduction defects and interstitial lung disease (ILD).

Methods: A 48-year-old male patient with SSc complicated by significant cardiac enlargement, third-degree atrioventricular block, heart failure, progressive ILD, and partial intestinal obstruction was included in the study. Prior treatments with mycophenolate mofetil (MMF), tacrolimus, and cyclophosphamide (CTX) had shown limited efficacy.

View Article and Find Full Text PDF

Background: Modulator therapy restores CFTR function and has led to health benefits for persons with cystic fibrosis (CF) (PwCF), including lower rates of pulmonary exacerbations. It is unknown if modulators affect lung function trajectories after inpatient treatment of pulmonary exacerbations (PEx).

Methods: We conducted a retrospective review of hospital encounters for PEx for subjects 6-25 years old with mild to moderate lung disease admitted to a large tertiary care center from 2014 to 2021 to capture hospitalizations of PwCF before and after starting modulators.

View Article and Find Full Text PDF

Dipeptidyl peptidase 1 (DPP1) inhibitors constitute a major advance in respiratory disease therapeutics. Through selective blockade of neutrophil serine protease (NSP) activation, these agents establish novel treatment paradigms for inflammatory respiratory conditions characterized by neutrophil-driven pathology. This comprehensive review examines the development status, clinical efficacy, and safety profile of DPP1 inhibitors in neutrophil-driven diseases, particularly non-cystic fibrosis bronchiectasis (NCFBE) and chronic obstructive pulmonary disease (COPD).

View Article and Find Full Text PDF

Traditional studies of pulmonary fibrosis (PF) have focused on alveolar epithelial cells injury and abnormal myofibroblast aggregation, but recent studies have revealed that imbalances in pulmonary capillary homeostasis also play pivotal roles in this disease. The pulmonary microvasculature, composed of aerocyte capillary (aCap) and general capillary (gCap) endothelial cells, forms the core structure of the alveolar-capillary membrane. It performs key roles in gas exchange and nutrient/metabolite transport, while modulating the trafficking of inflammatory factors and immune cells and regulating alveolar damage repair.

View Article and Find Full Text PDF

Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease.

Immune Netw

August 2025

Center for Metabolic and Degenerative Diseases, The Brown Foundation Institute of Molecular Medicine for Prevention of Human Diseases, UTHealth-McGovern Medical School, Houston, TX 77030, USA.

Complement anaphylatoxins C3a and C5a are potent immunomodulators whose impact extends well beyond their traditional roles in innate immunity. Acting through G protein-coupled receptors C3aR, C5aR1, and C5aR2, these peptides take part in coordinating immune cell recruitment, vascular tone, and tissue remodeling. Yet their functions are deeply context-dependent: while they play essential roles in microbial clearance and immune coordination, their overactivation contributes to immunopathology in a wide range of diseases.

View Article and Find Full Text PDF